摘要
目的:观察PELF方案治疗晚期胃癌的近期疗效、无进展生存期、总生存期及不良反应。方法:68例经病理组织学证实为腺癌的晚期胃癌患者,男54例,女14例,应用PELF联合化疗方案治疗:顺铂10～20mg/m2/d,iv,d1～5,表阿霉素(法玛新)50～80mg/m2,iv,d1,甲酰四氢叶酸(LV)100～200mg/m2,iv,d1～5,5FU500mg/m2,iv,d1～5,3～4周重复,平均接受3.5个周期(2～9周期)治疗。结果:19例Ⅲ期胃癌术后辅助化疗患者,14例随访至今仍存活,3年生存率52.9%。48例可评价客观疗效者中,CR3例,PR13例,SD19例,PD12例,总有效率33.3%。中位无进展生存期4.2个月,中位总生存期10.2个月。68例可评价毒性反应,Ⅲ～Ⅳ度中性粒细胞减少17.8%;Ⅲ度贫血1.5%,Ⅲ～Ⅳ度血小板减少3.0%;Ⅲ度恶心呕吐8.8%;脱发11.8%。结论:PELF治疗进展期胃癌较为安全有效,而且适合我国社会及经济情况。
Objective: To observe the clinic response rate, time to progression(TTP), overall survival (OS) and the toxicity of PELF regimen for advanced gastric cancer. Methods: A total of 68 patients with advanced gastric adenocarcinoma, including 54 male and 14 female, were treated with PELF chemotherapy regimen. It comprised of Epirubicin, 50~80mg/m2 intravenously (iv) bolus on day 1; Cisplatin 10~20mg/m2, iv, in 2-h infusion on days 1~5; leucovorin (LV) 100~200mg/m2, iv, in 2-h infusion on days 1~5; 5-Fu 500mg/m2, iv, in 4-h infusion on days 1~5; the cycles were repeated every 3~4 weeks and the first evaluation was done after two cycles. The median treatment cycle was 3.5 (ranged from 2 to 9). Results: Nineteen cases of gastric cancer in stage Ⅲ received adjuvant chemotherapy postoperation, 14 of them has been followed-up to date and still alive, and the 3-year survival rate was 52.9%. Fourty-eight patients were evaluable for response, which had 3 complete response (CR), 13 partial response (PR), 19 stable disease (SD), and 12 progression (PD). The overall response rate was 33.3%, the median TTP was 4.2 months, and the median OS was 10.2 months. All of the 68 patients were assessable for toxicity according to WHO standard. The incidence of grade Ⅲ~Ⅳ neutropenia, anemia, thromobocytopenia, vomiting and alopecia were 17.8%, 1.5%, 3.0%, 8.8% and 11.8%, respectively. Conclusion: PELF is an active and well tolerated regimen in treatment of advanced gastric cancer. Furthermore, it also meets the social and economic requirements in our country.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2005年第3期162-164,共3页
Chinese Journal of Clinical Oncology
